Transdermal Nicoderm patch — Competitive Intelligence Brief

Transdermal Nicoderm patch (Transdermal Nicoderm patch) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotine replacement therapy. Area: Smoking Cessation / Addiction Medicine.

marketed Nicotine replacement therapy Nicotinic acetylcholine receptors Smoking Cessation / Addiction Medicine Small molecule

Target snapshot

Transdermal Nicoderm patch (Transdermal Nicoderm patch) — Ottawa Heart Institute Research Corporation. Nicotine delivered transdermally binds to nicotinic acetylcholine receptors in the brain, providing nicotine replacement to reduce cravings and withdrawal symptoms during smoking cessation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Transdermal Nicoderm patch TARGET	Transdermal Nicoderm patch	Ottawa Heart Institute Research Corporation	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
patch + lozenge	patch + lozenge	University of Wisconsin, Madison	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Usual brand cigar	Usual brand cigar	Ohio State University Comprehensive Cancer Center	marketed		nicotinic acetylcholine receptors
Chantix	Varenicline Tartrate	Pfizer Inc.	marketed	Nicotinic receptor partial agonist	α4β2 neuronal nicotinic acetylcholine receptors
nicotine patch, labeled use	nicotine patch, labeled use	University of Vermont	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Nicotine Patch + Nicotine Gum	Nicotine Patch + Nicotine Gum	University of Wisconsin, Madison	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Fentanyl/Atropine/Succinylcholine	Fentanyl/Atropine/Succinylcholine	King Saud University	marketed	Anesthetic combination (opioid + anticholinergic + neuromuscular blocker)	Mu-opioid receptor (fentanyl); muscarinic acetylcholine receptors (atropine); nicotinic acetylcholine receptors at neuromuscular junction (succinylcholine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2035-10-19 — Chantix · 11224598 · Method of Use · US
• 2035-10-19 — Chantix · 10456396 · Formulation · US
• 2035-10-19 — Chantix · 9597284 · Method of Use · US
• 2035-10-19 — Chantix · 9532944 · Method of Use · US
• 2035-10-19 — Chantix · 9504644 · Method of Use · US
• 2035-10-19 — Chantix · 11911380 · Method of Use · US
• 2035-10-19 — Chantix · 11903943 · Method of Use · US
• 2035-10-19 — Chantix · 11903941 · Method of Use · US
• 2035-10-19 — Chantix · 9504645 · Formulation · US
• 2035-10-19 — Chantix · 11903942 · Formulation · US

Sponsor landscape (Nicotine replacement therapy class)

1. University of Wisconsin, Madison · 2 drugs in this class
2. Iowa City Veterans Affairs Medical Center · 1 drug in this class
3. Massachusetts General Hospital · 1 drug in this class
4. NYU Langone Health · 1 drug in this class
5. GlaxoSmithKline · 1 drug in this class
6. University of Hawaii · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. University of Vermont · 1 drug in this class
9. Ottawa Heart Institute Research Corporation · 1 drug in this class